These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20691957)

  • 21. Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions.
    Pauwels PJ; Gouble A; Wurch T
    Biochem J; 1999 Oct; 343 Pt 2(Pt 2):435-42. PubMed ID: 10510311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detecting constitutive activity and protean agonism at cannabinoid-2 receptor.
    Beltramo M; Brusa R; Mancini I; Scandroglio P
    Methods Enzymol; 2010; 484():31-51. PubMed ID: 21036225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective and divergent regulation of cortical 5-HT(2A) receptors in rabbit.
    Aloyo VJ; Dave KD; Rahman T; Harvey JA
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1066-72. PubMed ID: 11714896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation and characterization of highly constitutive active histamine H3 receptors.
    Takahashi K; Tokita S; Kotani H
    J Pharmacol Exp Ther; 2003 Oct; 307(1):213-8. PubMed ID: 12954820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: evidence for inverse agonism.
    Pauwels PJ; Tardif S; Wurch T; Colpaert FC
    J Pharmacol Exp Ther; 2000 Feb; 292(2):654-63. PubMed ID: 10640303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-hydroxytryptamine subtype 6 receptor modulators: a patent survey.
    Ivachtchenko AV; Ivanenkov YA; Tkachenko SE
    Expert Opin Ther Pat; 2010 Sep; 20(9):1171-96. PubMed ID: 20716023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inverse, protean, and ligand-selective agonism: matters of receptor conformation.
    Kenakin T
    FASEB J; 2001 Mar; 15(3):598-611. PubMed ID: 11259378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protean agonism at histamine H3 receptors in vitro and in vivo.
    Gbahou F; Rouleau A; Morisset S; Parmentier R; Crochet S; Lin JS; Ligneau X; Tardivel-Lacombe J; Stark H; Schunack W; Ganellin CR; Schwartz JC; Arrang JM
    Proc Natl Acad Sci U S A; 2003 Sep; 100(19):11086-91. PubMed ID: 12960366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Constitutive activity of 5-HT receptors: Factual analysis.
    De Deurwaerdère P; Bharatiya R; Chagraoui A; Di Giovanni G
    Neuropharmacology; 2020 May; 168():107967. PubMed ID: 31958408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constitutive activity in cannabinoid receptors.
    Fong TM
    Adv Pharmacol; 2014; 70():121-33. PubMed ID: 24931194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical antipsychotics and inverse agonism at 5-HT2 receptors.
    Sullivan LC; Clarke WP; Berg KA
    Curr Pharm Des; 2015; 21(26):3732-8. PubMed ID: 26044975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constitutive activity of G-protein coupled receptors: emphasis on serotonin receptors.
    Teitler M; Herrick-Davis K; Purohit A
    Curr Top Med Chem; 2002 Jun; 2(6):529-38. PubMed ID: 12052192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Constitutive activities and inverse agonism in dopamine receptors.
    Zhang B; Albaker A; Plouffe B; Lefebvre C; Tiberi M
    Adv Pharmacol; 2014; 70():175-214. PubMed ID: 24931197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities.
    Bosier B; Muccioli GG; Hermans E; Lambert DM
    Biochem Pharmacol; 2010 Jul; 80(1):1-12. PubMed ID: 20206137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.
    Berg KA; Clarke WP
    Int J Neuropsychopharmacol; 2018 Oct; 21(10):962-977. PubMed ID: 30085126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antihistaminergics and inverse agonism: potential therapeutic applications.
    Monczor F; Fernandez N; Fitzsimons CP; Shayo C; Davio C
    Eur J Pharmacol; 2013 Sep; 715(1-3):26-32. PubMed ID: 23831018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists.
    Joubert L; Claeysen S; Sebben M; Bessis AS; Clark RD; Martin RS; Bockaert J; Dumuis A
    J Biol Chem; 2002 Jul; 277(28):25502-11. PubMed ID: 11976337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inverse agonism and its therapeutic significance.
    Khilnani G; Khilnani AK
    Indian J Pharmacol; 2011 Sep; 43(5):492-501. PubMed ID: 22021988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists.
    Patel M; Finlay DB; Glass M
    Cell Signal; 2021 Feb; 78():109865. PubMed ID: 33259937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An aromatic region to induce a switch between agonism and inverse agonism at the ghrelin receptor.
    Els S; Schild E; Petersen PS; Kilian TM; Mokrosinski J; Frimurer TM; Chollet C; Schwartz TW; Holst B; Beck-Sickinger AG
    J Med Chem; 2012 Sep; 55(17):7437-49. PubMed ID: 22920150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.